Simran Arora

Eli Lilly's Retatrutide Shows Record Weight Loss In Third Phase Of Trials

Weight loss drugs (2)

<span>Retatrutide</span>, <span>Eli Lilly</span>’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest <span>weight loss</span> ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.

Also Read: <a href="https://www.healthandme.com/health-news/dahi-lover-study-says-probiotics-in-it-may-reduce-microplastics-in-your-body-article-154374091" data-type="tilCustomLink" target="_blank">Dahi Lover? Study Says Probiotics In It May Reduce Microplastics In Your Body</a>

Retatrutide is similar to drugs like <span>Zepbound</span> and <span>Wegovy</span> that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.

Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a <span>BMI</span> of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.

<strong>Read more: </strong><a href="https://www.healthandme.com/health-news/meet-retatrutide-the-unapproved-cousin-of-ozempic-that-supports-weight-loss-differently-article-154187472" data-type="tilCustomLink" target="_blank">Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss Differently</a>

Retatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.

<h2>What were the side effects of Retatrutide?</h2>

On the downside, there were some side effects too. Retatrutide users experienced the following side effects:

<ol><li>Diarrhoea</li><li>Nausea</li><li>Constipation</li><li>Urinary tract infections</li><li>Uncomfortable skin sensations</li></ol>

These have, however, been seen with GLP-1 drugs.

<h2>New weight-loss drug coming soon?</h2>

Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.

Health Conditions A-Z

health

weight-loss-drugs-2

retatrutide

Eli lilly

weight loss drugs

weight loss

wegovy

eli lillys

zepbound

ebola-outbreak-kerala-to-keep-visitors-from-affected-countries-under-surveillance-for-21-days

Ebola Outbreak: Kerala To Keep Visitors From Affected Countries Under Surveillance For 21 Days

high-bp-1

Post-Pandemic Effect: Why 30-Something Delhi-ites Are Struggling With High BP

preeclampsia-is-preventable-treatable-yet-its-indias-3rd-leading-cause-of-maternal-deaths-aiims-doctor

Preeclampsia Is Preventable & Treatable. Yet It’s India’s 3rd Leading Cause Of Maternal Deaths, Says AIIMS doctor

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Retatrutide, Eli Lilly’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.Also Read: Dahi Lover? Study Says Probiotics In It May Reduce Microplastics In Your BodyWhat is Retatrutide?Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.Read more: Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss DifferentlyRetatrutide's resultsRetatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.What were the side effects of Retatrutide?On the downside, there were some side effects too. Retatrutide users experienced the following side effects:DiarrhoeaNauseaConstipationUrinary tract infectionsUncomfortable skin sensationsThese have, however, been seen with GLP-1 drugs.New weight-loss drug coming soon?Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.